Maritz Appoints Chief Behavioral Officer (CBO), Charlotte Blank – Yahoo Finance

ST. LOUIS--(BUSINESS WIRE)--

Maritz announced today the appointment of Charlotte Blank to chief behavioral officer (CBO) of the company. In this new role, Blank will lead the companys thought leadership, research and application of behavioral science. Maritz joins a growing population of progressive businesses dedicating a c-suite executive to behavioral science in business.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170428006071/en/

At our core, were a behavior company. The scientific study of human behavior is a central component of Maritz DNA, and ingrained in the design of our client solutions, said Steve Maritz, chairman and CEO of Maritz. Our expertise in this space has grown tremendously over the years. With Charlotte as our CBO, we can emphasize to the market and our clients the role behavioral science plays in powering our solutions and improving their business performance.

As Maritz CBO, Blank will forge the connection between academic theory and applied business practice, elevating the use of field research to propel Maritz people solutions and client programs. Her responsibilities will include growing Maritz network of world-class academic partners and focusing on opportunities for field research with these academics and clients.

Maritz has always been a leader in understanding, enabling, and motivating behavior, said Charlotte Blank, newly appointed chief behavioral officer of Maritz. Its exciting to see us elevate the study of behavioral science as the foundation for our expertise in what drives people.Our clients count on us to bring them the latest human science advancements to design higher-performing programs that drive behavior and business results.

Prior to Maritz, Blank led programs in neuromarketing, social media, and global branding during herten years in the media and automotive industries, including stints at Turner Broadcasting, and General Motors. She earned a Bachelor of Science degree in Neuroscience and Behavioral Biology from Emory University, and a Master of Business Administration from Harvard Business School.

To learn more about Charlotte Blanks perspective on behavioral science in business, view a recent article here and follow Charlotte Blank on Twitter @CharlotteBlank.

About Maritz

St. Louis-based Maritz is a sales and marketing services company, which helps businesses achieve their full potential through inspiring and motivating employees, channel partners and customers. Maritz companies provide market and customer research; customer loyalty, sales incentives and employee rewards and recognition programs; and meeting, event and travel incentive services to Fortune 500 companies and beyond. For more information, visit maritz.com or contact us at 1-877-4MARITZ.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170428006071/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170428006071/en/

Read the original post:
Maritz Appoints Chief Behavioral Officer (CBO), Charlotte Blank - Yahoo Finance

Higher education notebook – Arkansas Online

ASU plans master's in athletic training

Arkansas State University will start its new master's degree program in athletic training.

The Jonesboro campus currently offers a Bachelor of Science degree in athletic training, which is housed under the College of Education and Behavioral Science, but will phase that out. The new master's program -- which is now only offered by the University of Arkansas, Fayetteville -- will be under Arkansas State's College of Nursing and Health Professions.

The university plans to hire one faculty member by July 1, 2018, for the new program.

The Arkansas Higher Education Coordinating Board approved the new master's program earlier this month. About 70 percent of certified athletic trainers have a master's degree, according to the National Athletic Trainers' Association.

Arkansas State anticipates 12 students to enroll in the program starting in the summer of 2018. Applicants must have a bachelor's degree in no particular field of study, but the university said required classes in some fields -- including biology and exercise science -- are more aligned with the master program's prerequisite requirements.

UCA, 2 colleges join in degree program

The University of Central Arkansas has partnered with two community colleges to help students finish a bachelor's degree in elementary or middle-level education.

The Conway university has created "2+2" agreements with North Arkansas College in Harrison and Northwest Arkansas Community College in Bentonville for the programs.

Students who have completed an associate of science in education at North Arkansas or an associate of science in liberal arts and sciences at Northwest Arkansas are eligible for the transfer program. Students must be accepted into UCA and into UCA's Teacher Education program, must show proof of minimum ACT or SAT college entrance exams and must have a cumulative grade-point average of at least 2.7.

North Arkansas will have to develop two courses, one in earth science and another in exceptional child, and will have to retool its child growth and development course, according to the agreement. Northwest Arkansas will have to add an earth science course.

The agreement will be in effect this fall, and any student currently attending either institution can start at any time, as long as he meets the requirements.

Metro on 04/29/2017

Print Headline: ASU plans master's in athletic training UCA, 2 colleges join in degree program

Continue reading here:
Higher education notebook - Arkansas Online

Anti-Aging Benefits of Yoga – Medical News Bulletin

Researchers in India report that yoga postures, breathing disciplines and meditation may be the key to prolonging that proverbial fountain of youth. Biomarkers found in human blood samples drawn during a clinical trial showed the anti-aging benefits of practicing these ancient holistic practices.

In the Yoga and Meditation Based Lifestyle Intervention (YMLI) clinical trial, scientists enrolled a homogenous, seemingly healthy group of 96 men and women aged 30-65 years old, who had not experienced any significant lifestyle or physical challenges over the preceding three months between August 2015 and May 2016. Once enrolled, participants had 5 milliliters of fasting venous blood drawn to establish baseline markers for a range of primary and secondary aging characteristics. They next practiced yoga and meditation in the 12-week program to measure the disciplines anti-aging benefits.

During the trials initial 14 days, the group received instructions from registered, specialized yoga instructors for five days each week at the AIIMS health clinic in New Delhi, India. The YMLI instructions incorporated Hatha and Raja yoga techniques including physical postures, breathing exercises and meditation into their 90-minute classes. Following yoga, a 30-minute lecture focused on the importance of a healthy lifestyle and diet in warding off conditions like cancer, diabetes and cardiovascular diseases, among others.

The participants then were required to continue their practices at home for the subsequent 10 weeks and were responsible for self-monitoring their progress in a diary or by regular telephone conversation. At the trials conclusion, another 5 milliliters venous blood was drawn to compare the pre- and post-YMLI levels of various markers.

The scientists analyzed the changes in primary and secondary aging characteristic found in participants blood before and after the 12-week program. Primary measures included DNA damage that leads to metabolic instability, oxidative stress levels, total antioxidant levels, among others. As secondary factors, they examined cortisol levels a reading of stress responsiveness inflammation and cellular plasticity, among others.

The researchers hypothesis was confirmed when they examined the trial participants blood at the end of the 12-week trial. In every instance, YMLI was associated with changes for the better, indicating a slow-down of the cellular aging process. The authors hailed their clinical trial as the first to investigate the effects of YMLI on age-related biomarkers. Almost no gender-based biomarker differences appeared in the trial. This trial serves as a springboard bringing the practice of yoga and meditation further into mainstream science surrounding aging and disease prevention.

The study is limited by its small size, homogenous population and lack of a similarly sized control group.

The trials findings were published online on Jan. 16, 2017, by Oxidative Medicine and Cellular Longevity.

So, you may want to bend and twist into a yogic position, breathe deeply and meditate in your individual quest to recapture that elusive fountain of youth.

Written By:Susan Mercer Hinrichs, MA, MBA, CPhT

Read more here:
Anti-Aging Benefits of Yoga - Medical News Bulletin

Google is super secretive about its anti-aging research. No one knows why. – Vox

In 2013, Time magazine ran a cover story titled Google vs. Death about Calico, a then-new Google-run health venture focused on understanding aging and how to beat it. We should shoot for the things that are really, really important, so 10 or 20 years from now we have those things done, Google CEO Larry Page told Time.

But how exactly would Calico help humans live longer, healthier lives? How would it invest its vast $1.5 billion pool of money? Beyond sharing the companys ambitious mission to better understand the biology of aging and treat aging as a disease Page was vague.

I recently started poking around in Silicon Valley and talking to researchers who study aging and mortality, and discovered that four years after its launch, we still dont know what Calico is doing.

I asked everyone I could about Calico and quickly learned that its an impenetrable fortress. Among the little more than a dozen press releases Calico has put out, there were only broad descriptions of collaborations with outside labs and pharmaceutical companies most of them focused on that overwhelmingly vague mission of researching aging and associated diseases. The media contacts there didnt so much as respond to multiple requests for interviews.

People who work at Calico, Calicos outside collaborators, and even folks who were no longer with the company, stonewalled me.

We should pause for a moment to note how strange this is. One of the biggest and most profitable companies in the world has taken an interest in aging research, with about as much funding as NIHs entire budget for aging research, yet its remarkably opaque.

Google also prides itself for being a leader on transparency and for its open culture. And were living in a time when the norms in science, particularly biomedical science, are centered around openness and data sharing. But these values have somehow eluded Calico.

For now, I think its safe to say Google has not solved aging. Or if it did, they havent told anybody.

Its not unusual for new startups to be stealthy for a period while they get going, but theres usually some public statement with specific details about the technology or science being developed, strategies and targets. That Calico wont say what its doing bothers leading aging researchers. They expressed confusion or frustration about Calicos stealthiness, and said the secrecy is not productive for science.

Eric Topol is a cardiologist who studies aging and the director of Scripps Translational Science Institute. Topol knows some of the scientists at Calico from their pre-Calico days. Theyre hyper secretive, he said. Since they moved to Google, he cant seem to reach them. I have invited them to speak at our program we have on genomic medicine. They say no, they cant talk about what theyre doing. I am not sure why thats the case.

There were no clinical trials or patents filed publicly under the Calico brand that I could find, and out of the 22 papers published by the company and its affiliates, only about half related to aging and many were review articles (not original research).

Nir Barzilai, a geneticist and one of the leading researchers in aging based at Albert Einstein College of Medicine, said the publications didnt give him any special insights into what Calico is up to. Our field is interested in delaying aging and by that, delaying disease. [It seems] they are not doing that, he said. Its weird they dont come to us, look at our patents We have resources, we are eager to do partnerships and form bio-techs. And nobody from Calico talks to us.

Other top researchers on aging told me much the same. I dont interact with them, Felipe Sierra, director of the division of aging biology at NIHs National Institute on Aging, said. They dont want to interact with me. I ignore them as much as they ignore me. He also invited Calico scientists to present at NIH. They come to the meeting but they dont talk about what they are doing [They] wouldnt even talk about general directions [of their research].

There are a few potential explanations for Calicos secrecy. Among them: that Calico is just waiting for a big reveal. A December article in the MIT Technology Review, which was also scant on details about Calicos anti-aging science, hinted that might be the case:

[David] Botstein [the Calico Chief Scientific Officer] says a best case scenario is that Calico will have something profound to offer the world in 10 years. That time line explains why the company declines media interviews. There will be nothing to say for a very long time, except for some incremental scientific things. That is the problem.

But avoiding media hype does not require secrecy among scientific colleagues. If Calicos scientists were truly interested in pushing the boundaries of science, they might think about using some of the best practices that have been developed to that end: transparency, data sharing, and coordinating with other researchers so they dont go down redundant and wasteful paths.

As Topol said, Secretive research is pass. The world has moved on to fully demonstrate the value of openness, transparency, and avoidance of insular thinking.

There are other possible explanations for the stealthiness. A recent news release from Calico announced a partnership with C4 Therapeutics to work on coming up with drugs for "diseases of aging," such as cancer one of a number of drug company partnerships Calico has formed. If Calicos now focused on drug development, then a degree of secrecy might make sense. (Drug companies typically develop their products quietly to stay ahead of the competition.)

But researchers dont buy that explanation, either. The researchers [Calico] hired are using models such as yeasts, nematodes, and naked mole rats, said Barzilai. These are not the models that are relevant for drug development. Developing cures also doesnt fall in line with the companys original mission to treat aging as a genetic disease instead of hunting for treatments for age-related diseases.

Another potential reason for the lack of transparency the one I find most compelling is that its the company culture. Art Levinson, the CEO of Calico, is also chair of the board of Apple Inc. and was close to Steve Jobs, who was renowned for his clandestine approach to research and development and running a business. Its possible that Levinson has made secrecy part of Calicos DNA, the way its part of Apples DNA.

Perhaps Calico will one day justify its secrecy, Topol said. But at this point, he added, I dont understand it. Potentially withholding information about advances in biomedical science or cures for diseases is unacceptable: Lives are ultimately at stake. Anything that slows down progress in biomedical research cant be condoned.

For that reason, Id like to humbly invite Calico or people who have worked with the company to share what they are up to. I promise we wont hype it.

Have information about Calico? You can send me tips over email at julia.belluz@vox.com or secure PGP. (My key: 0AC1 64FA E095 851B 112A 0670 6D24 B5A4 56ED 285E)

Update Friday April 28, 2:34 p.m.: Thanks to reader tips and additional searches in PubMed, weve located and linked to several Calico papers we werent aware of when we first published this story on Thursday. I flagged the papers with the researchers quoted in this story who said they did not change their assessment of Calico.

See the article here:
Google is super secretive about its anti-aging research. No one knows why. - Vox

No Excuses: Exercise Can Overcome the ‘Obesity Gene’ – Glens Falls Post-Star

THURSDAY, April 27, 2017 (HealthDay News) -- Even if obesity is "in your genes," regular exercise can help keep extra pounds at bay, a new study suggests.

Researchers found that when people carried a particular gene variant that raises obesity risk, regular exercise seemed to reduce the effects of their DNA -- by about one-third.

The gene in question is known as FTO. Studies show that people with a particular variant of the gene have a heightened risk of obesity.

But the gene's effects are not huge, or written in stone. Research has found that people who carry two copies of the FTO variant (one inherited from each parent) weigh about 6.5 pounds more than non-carriers, on average.

The new findings underscore one way to counter the gene's impact: Exercise.

"There are genes that appear to directly impact weight, but the effects are small," said lead researcher Mariaelisa Graff, of the University of North Carolina at Chapel Hill. "You still have a lot of choice over your behavior."

The study results are not exactly surprising, according to Dr. Timothy Church, an obesity researcher who was not involved in the work.

"This shows, once again, that genes are not your destiny," said Church. He is a professor of preventative medicine at Louisiana State University's Pennington Biomedical Research Center.

Church said regular exercise is particularly key in preventing excess weight gain in the first place -- and in keeping the pounds off after someone loses weight.

Exercise is less effective in helping obese people shed weight, Church said. Diet changes are the critical step there.

But the bottom line is that exercise matters, regardless of your genes, according to Dr. Chip Lavie, of the John Ochsner Heart and Vascular Institute, in New Orleans.

Lavie, who was not involved in the study, pointed to findings from his own research.

"[We] have published data that suggests the main cause of increasing obesity over the past five decades is the dramatic decline in physical activity," he said.

Gym memberships aside, Americans these days are less active at work, at home (through housework) and during leisure time, according to Lavie.

And the benefits of exercise go beyond weight control, he stressed. Physical activity boosts people's fitness levels -- which, Lavie said, is critical in preventing heart disease and living a longer, healthier life.

The new findings are based on over 200,000 adults, mostly of European descent, who'd taken part in previous health studies.

Graff and her colleagues analyzed information on their weight and exercise habits, and looked at how those factors "interacted" with 2.5 million gene variants.

FTO is the gene that is most strongly linked to obesity, Graff said.

And overall, her team found, active people who carried the obesity-linked FTO variant appeared more resistant to its effects than sedentary people.

On average, exercise weakened the variant's effects by about 30 percent, the researchers reported in the April 27 issue of PLOS Genetics.

There were some hints that exercise also affected some other weight-related genes. But the only clear relationship was with the FTO variant, according to Graff.

That, she noted, could be related to the broad way the study looked at exercise. The 23 percent of people who were least active were considered "inactive," while everyone else was deemed "active."

Church said he thinks research into the genetics of body weight will increasingly become useful.

If certain gene variants affect people's response to a low-carb diet or aerobic exercise, for example, that could help in "tailoring" weight-loss plans, he suggested.

"The science is rapidly evolving," Church said, "and there's still a lot to learn. But I think that's the direction this is going."

Link:
No Excuses: Exercise Can Overcome the 'Obesity Gene' - Glens Falls Post-Star

Blood test offers hope for better lung cancer treatment – Sioux City Journal

BOSTON (AP) Researchers have taken an important step toward better lung cancer treatment by using blood tests to track genetic changes in tumors as they progress from their very earliest stages.

With experimental tests that detect bits of DNA that tumors shed into the blood, they were able to detect some recurrences of cancer up to a year before imaging scans could, giving a chance to try new therapy sooner.

It's the latest development for tests called liquid biopsies, which analyze cancer using blood rather than tissue samples. Some doctors use these tests now to guide care for patients with advanced cancers, mostly in research settings. The new work is the first time tests like this have been used to monitor the evolution of lung tumors at an early stage, when there's a much better chance of cure.

Only about one third of lung cancer cases in the United States are found at an early stage, and even fewer in other parts of the world. But more may be in the future as a result of screening of longtime smokers at high risk of the disease that started a few years ago in the U.S.

Early-stage cases are usually treated with surgery. Many patients get chemotherapy after that, but it helps relatively few of them.

"We have to treat 20 patients to cure one. That's a lot of side effects to cure one patient," said Dr. Charles Swanton of the Francis Crick Institute in London.

The new studies he led suggest that liquid biopsies might help show who would or would not benefit from chemotherapy, and give an early warning if it's not working so something else can be tried.

Cancer Research UK, a charity based in England, paid for the work, and results were published online Wednesday by Nature and the New England Journal of Medicine .

To be clear: This kind of care is not available yet the tests used in these studies are experimental and were customized in a lab to analyze the genes in each patient's cancer. But the technology is advancing rapidly.

The company that generated the tests for the study in Nature California-based Natera Inc. plans to offer the tests for research by universities and drug companies later this year and hopes to have a version for routine use in cancer care next year.

"This is coming, and it's coming fast," said Dr. David Gandara, a lung specialist at the University of California, Davis, who had no role in the studies but consults for two companies developing liquid biopsies. A test that could spare many people unnecessary treatment "would be huge," he said.

In the studies, researchers analyzed tumors from about 100 people with non-small cell lung cancer, the most common form of the disease. Even in these early-stage cases, they found big variations in the number of gene flaws, and were able to trace how the tumors' genes changed over time.

People with many gene or chromosome problems were four to five times more likely to have their cancer return, or to die from their disease within roughly two years.

They also looked at 14 patients whose cancers recurred after surgery, and compared them to 10 others whose did not. Blood tests after surgery accurately identified more than 90 percent of them that were destined to relapse, up to a year before imaging tests showed that had occurred.

The results suggest that using liquid biopsy tests to help select and adjust treatments is "now feasible," at least from a scientific standpoint, the authors write.

A big issue is cost, though. Liquid biopsies sold now in the U.S. cost nearly $6,000. Tests that more narrowly track a patient's particular tumor gene changes, like the one in these studies, may cost less. They may save money in the long run, by preventing futile treatment, but this has yet to be shown.

Go here to read the rest:
Blood test offers hope for better lung cancer treatment - Sioux City Journal

Hilarious and emotional: our inaugural Chemistry Stories event – Royal Society of Chemistry

Yorkshire puddings and Niagara Falls

For the first Chemistry Stories event, eight chemists and non-chemists told their chemistry-related stories at a gathering in the University of Cambridge Chemistry Department. These included a humanising tale of a Yorkshire pudding "defeating" chemistry and the hilarious description of a final year postgrads desperation for results causing "Niagara Falls" in the University of Cambridge Chemistry Department.

Edwin Silvester, our news and media manager and former BBC journalist, told the story of how he went from hating science in senior school and accusing his friend of being "too interesting to do science and maths A-levels" to being inspired by a group of kids doing science experiments in a shopping centre finally ending up working with us at the Royal Society of Chemistry.

As well as the many lighthearted and funny stories, there was also an emotional element to the evening when Sarah Madden described how chemistry taught her to "try, try again" after overcoming illness and finishing her chemistry degree.

The event was conceived and coordinated by Susan Vickers, Public Engagement Executive at the Royal Society of Chemistry and the person responsible for using the PAC research to revise our public engagement strategy.

As Susan explains: "I was so impressed by the storytellers at our event; it can be daunting to tell such personal stories to an audience!

"The stories were so entertaining and great at demonstrating the human and emotional side of chemistry. Stories are more interesting, understandable, and memorable than lectures and we plan to use this approach more in the future."

The next Chemistry Stories event will be in Burlington House on Tuesday 30 May and will be packed with more chemistry accounts and anecdotes. For more information email Susan Vickers (using the "Public outreach" details on the left of this page)or check out ourevents page.

See the original post here:
Hilarious and emotional: our inaugural Chemistry Stories event - Royal Society of Chemistry

Chemistry building for Herd football team | Marshall Sports | herald … – Huntington Herald Dispatch

HUNTINGTON - Following the 2016 season, there was undoubtedly many areas where Marshall University's football team needed improvement to get back to its winning ways.

Marshall had a 3-9 season in 2016, following three consecutive seasons with at least 10 victories.

Some of the problems in 2016 involved techniques and nuances of the game, but the biggest need was about team chemistry - something that deteriorated as the 2016 season progressed.

As losses piled up, team cohesion broke down - so much so that at one point Marshall head coach Doc Holliday went on to say the Thundering Herd "wasn't a good team right now." In the winter months and into spring practice much of the focus has been on that area.

"I see us getting back to that camaraderie across the ball, outside of your own little world," said Bill Legg, the Marshall offensive coordinator. "That's a good thing to see, for sure. Quarterbacks spend all their time together. Wide receivers spend all their time together. Offensive linemen spend all their time together. That cohesion is natural, but this year, there's a lot more coming from everybody."

Team cohesion is important because when things start to go bad like they did in 2016 it is easy for one position group of players to begin pointing fingers at another position when the team cohesion isn't present.

Nearly all of Marshall's players involved in the 2016 season had never experienced much adversity associated with losing. When things went bad, nobody - veterans included - really knew how to handle it, and it was a tough situation for all.

"There was a mindset that 'We're just going to do it again because we are Marshall and we have an M on our helmet,'" Legg said. "Reality, all of the sudden was, 'Dude, you've got to go and take it because we've got a target on our back every single time we step on the field because we are Marshall.'

"You don't win games because we are Marshall. You win games because you've got really smart, tough, gritty football players that love each other wearing Marshall helmets that go out to compete for four quarters."

During the offseason and this spring Marshall strength and conditioning coach Luke Day put players in situations that were so demanding and tough they had to learn to lean on each other for support to make it through, which helped build chemistry.

"Coach Day has done not just a phenomenal job getting them bigger and stronger, but also with life lessons," Legg said. "It's sinking in and it is starting to feel - it's not all the way there, yet - but it's starting to feel like it felt two years ago, three years ago, four years ago."

Differences have been visible throughout the spring sessions as players from different positions congratulate effort as the team grows.

Those instances included quarterback Chase Litton coming off the sideline to congratulate defensive lineman Channing Hames for a sack, running back Keion Davis congratulating the linebackers for good tackles and wide receivers acknowledging secondary players when they make plays.

Those gestures can be the difference between success and failure on the field this fall.

"If we can just stay the course individually and collectively, then we give ourselves a chance," Legg said. "We could go from having the biggest drop-off to having the biggest turnaround."

Marshall puts the wraps on spring practice with a 9:15 a.m. Saturday scrimmage.

Visit link:
Chemistry building for Herd football team | Marshall Sports | herald ... - Huntington Herald Dispatch

Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M – FinSMEs (blog)


FinSMEs (blog)
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M
FinSMEs (blog)
Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at 64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d'Amorage) managed by Bpifrance under the ...

Link:
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M - FinSMEs (blog)

University of Maryland grad student restores movement to mice crippled with multiple sclerosis – Baltimore Sun

Crippled by multiple sclerosis, the lab mice's hind legs and tails were limp with paralysis, but Lisa Tostanoski had an idea about how she could treat them.

With a tiny needle, the doctoral student at the University of Maryland, College Park injected the mice with a dose of time-released medicine. Two weeks later the mice were scampering around their cages.

"They were able to stand up on their hind legs," Tostanoski said. "We reversed the paralysis."

The treatment, a complex combination of immunology and engineering, earned Tostanoski, 26, a prestigious Lemelson-MIT Student Prize, awarded to her and eight other students and teams earlier this month. The prize for the most promising young inventors in America awards her $15,000 for her medical invention to reverse symptoms of debilitating autoimmune diseases such as multiple sclerosis. Her novel approach has shown promise for developing treatments in an area that has long eluded researchers.

"If her invention that she's working on proves successful, it's a game changer," said Stephanie Couch, executive director of the Lemelson-MIT Program. "She didn't shy away from something that seems big and daunting."

Autoimmune diseases occur when a person's immune system mistakes healthy cells in the body for a foreign threat and attacks the tissue. With multiple sclerosis a disease afflicting more than 2.3 million people worldwide the immune system's defense cells attack the fatty myelin sheaths that cover nerves. Researchers don't know why these confused "T-cells" attack. But persistent barrages can damage nerves, causing muscles to weaken and stiffen, and lead to paralysis.

Doctors routinely treat multiple sclerosis patients with medicine to suppress the entire immune system and stave off attacks. But this strategy has widespread and often dangerous side effects in the body, and the benefits diminish over time.

Tostanoski, a McDonogh School alumnae from Catonsville, working in University of Maryland bioengineering lab, has embraced a different approach: transform the T-cells.

She began experimenting five years ago to develop a method to target the bad T-cells. Such a treatment would transform care for millions of people with multiple sclerosis.

"It's the Holy Grail of MS. Finding the exact T-cells that are causing the disease and getting rid of them could be close to a cure," said Bruce Bebo, executive vice president for research at the National Multiple Sclerosis Society in Waltham, Mass. "By selectively targeting the T-cells, you might be able to stop MS in its tracks."

The National Multiple Sclerosis Society has spent nearly $650,000 to fund Tostanoski's work at the Jewell Research Lab in College Park. Elsewhere, researchers are trying to develop similar pinpoint treatments that leave immune systems unscathed. The society has committed $80 million over the next four years to fund more than 300 research projects around the country.

Rather than suppressing the bad T-cells, Tostanoski's method aims to change the cells from foe to friend within the lymph nodes. These glands swell to produce defense cells when a person becomes sick.

"Think of the lymph nodes like a classroom," she said. "Cells that recognize myelin learn to mature and become inflammatory, then travel out of the lymph node to the brain where they attack."

She injected tiny fragments of myelin into this lymph node classroom. But her breakthrough came when she encapsulated the fragments with a coating that gradually wears down to prolong the release of myelin.

"You're basically keeping the stuff around longer," said Christopher Jewell, an associate professor of bioengineering who runs the College Park lab. "If you just inject something in there, it could flow out and be gone."

T-cells that develop in the presence of myelin don't attack it, though researchers don't know why. These cells will leave the lymph nodes and actually defend myelin. They also will calm the attacking cells.

The concept was born from theories that injections with low doses of bee pollen will diminish someone's allergy to bees. In two weeks of myelin treatments, the lab mice gradually recovered.

"What's really unique about what Lisa's working on is depositing in the lymph node and controlling the release," said Jewell, her academic adviser.

By focusing on multiple sclerosis, Tostanoski took on a large and vexing medical riddle, which attracted the Lemelson prize judges. Among the recent winners were students who developed a folding drone, an advanced prosthetic foot, a protein to fight superbug bacteria, and a portable device to convert text to Braille.

Multiple sclerosis is two to three times more common in women than men, according to the society. Most people are diagnosed between the ages of 20 and 50. The average American has about a one in 750 chance of contracting multiple sclerosis, according to the MS society.

Further research remains before Tostanoski's treatment is tested on people with MS. Researchers in the College Park lab plan to next test her methods on human lymph nodes removed during biopsies.

Tostanoski expects to receive her Ph.D. in bioengineering in the coming months, and she intends to find a research job with a university and one day become a professor. Researchers at the University of Maryland will carry on her work.

For now, she's relishing her award from the Lemelson judges. She learned of their decision by voice mail.

She was busy in the lab when they called.

tprudente@baltsun.com

See the rest here:
University of Maryland grad student restores movement to mice crippled with multiple sclerosis - Baltimore Sun

ROSTHERNE, LEAD THE MEDICAL ANTI-AGING – Press Release … – Digital Journal

According to statistics, European womens and mens skin begin to enter into the anti-aging process at the age of 25 and 27, respectively. Anti-aging cosmeceuticals have been more and more favored in the market. Skin aging is the result of endogenous aging and exogenous aging. The initial anti-aging skin care products were mainly based on application of vitamin, such as the brand Dr. Brandt Skincare in America. At the beginning of the 21st century, extraction of active substance from plants had been widely used in the anti-aging skin care products, among which the brand SkinCeuticals was the most famous one. With the development of gene therapy and biological cell therapy technology, however, the biological cell therapy technology has been gradually applied to cosmeceuticals, among which the British brand ROSTHERNE is the representative.

ROSTHERNE is one of three main cosmeceutical brands (ROSTHERNE, HENLEAZE and VINSTRA) of EVIGT SOLSKIN COSMECEUTICALS CO., LTD. Different from the three elements of anti-aging namely precaution, protection and restoring emphasized by SkinCeuticals, ROSTHERNE focuses more on four dimensions namely restoring, fading, activation and strengthening for anti-aging research, and pays more attention to the main direction of refreshing normal physiological function of cell by human cell engineering and biomedical technology, so that youth could be continued fundamentally.

The story behind ROSTHERNE brand

ROSTHERNE brand originated from Rostherne Mere, the British National Nature Reserve and seclusion of the nobility for more than a hundred years, behind which the legend of immortal mermaid could be found. The Doctor of Medicine Jones and the aristocratic princess Ansel escaped from the manor for love and lived a displaced life. In order to make Ansel who became toilworn day by day rejuvenative, Dr. Jones came to Rostherne Mere each Easter to wait the mermaid who could give the secret of being immortal. Finally, he heard the lively bell under the water and saw rebirth of all things, so he extracted the most original anti-aging product from the native plant around the lake and let Ansel recover her youth look. They established a clinic of love to remember the mermaid with gratitude for her gift. The land around the clinic was planted with many roses, so that their love could be transmitted and the beauty could be lasting.

The anti-aging products of ROSTHERNE were developed by a group of professional dermatologists and researchers in the fields of cell, molecular biology and biophysics. And a series of effective anti-aging products were developed by them with their unique cell activation and regeneration technology as the core technology. The unique new technology of Renee Expert TM combines various plant stem cells, EGF, yeast extract, coenzyme Q10 and other anti-aging and anti-oxidation products with theory of biological cell medicine, and realizes promotion of 3D anti-aging by its superb technology. It fully activates collagen and makes the damaged skin recover its vitality.

The anti-aging effect of ROSTHERNE has been spread from England to the whole world. Today, ROSTHERNE has been introduced into America, France, Germany, Netherlands, Australia, New Zealand, Canada and Hong Kong successively. It has been increasingly praised highly by dermatologists, medical cosmetology industry and customers worldwide. ROSTHERNE constantly explores the active anti-aging elements of the ultimate effect with a rigorous scientific attitude, keeps its leading position in the anti-aging industry, and transmit Dr. Joness spirit of Sharing love, lasting beauty.

Media Contact Company Name: EVIGT SOLSKIN COSMECEUTICALS CO., LTD Contact Person: Ryan Email: Evigtsolskin@outlook.com Phone: +44?0?1428 656600 Country: United Kingdom Website: http://www.evigt-solskin.com

See the article here:
ROSTHERNE, LEAD THE MEDICAL ANTI-AGING - Press Release ... - Digital Journal

Chili Pepper and Marijuana Soothe Gut Inflammation – Anti Aging News

Researchers at the University of Connecticut have discovered a chemical compound that could lead to new treatments for diabetes and gastrointestinal conditions. The research team, led by Professor of Immunology and Medicine Pramod Srivastava from the University of Connecticut School of Medicine, published their official findings in the April 24 issue of the Proceedings of the National Academy of Sciences journal.

Anandamide Production

Capsaicin is a chemical compound contained in spicy chili peppers. This chemical is responsible for the sensation of heat felt when they are consumed. The chemical binds to brain receptors, called TPRV1 receptors, to signal the sensation of heat from the tongue to the brain. TPRV1 receptors are also found in the gastrointestinal tract.

As part of their research, the team administered capsaicin to lab mice. These mice were found to have less inflammation in the gastrointestinal tract. Some mice who previously showed signs of Type 1 diabetes showed normal blood sugar levels after the trials.

The results are contributed to the capsaicin binding with TPRV1 receptors in the gastrointestinal tract. The binding process prompts the receptors to produce the chemical anandamide. This chemical soothes and relaxes the gastrointestinal tract. Researchers could repeat their original results by feeding anandamide directly to the lab mice, rather than using chili peppers.

Researchers do not fully understand how the chemical causes the immune system and brain to interact.

Anandamide and cannabinoids are chemically similar. When a person consumes marijuana, anandamide receptors in the brain react to the presence of cannabinoids. This produces feelings of euphoria and relaxation, or a high. Marijuana consumption causes anandamide production.

Anandamide and the Gastrointestinal Tract

While the team has not uncovered the mechanism that allows the brain to communicate with the immune system, they do understand how it helps heal the gastrointestinal tract.

There are other receptors that react to anandamide. These signal the production of immune cells called macrophages. These cells reduce inflammation. Higher anandamide levels correlate with higher macrophage presence, which can mean a significant reduction in inflammation. Anandamide and macrophage production can positively affect conditions in the esophagus, stomach, and pancreas.

Current trials are testing the effect of anandamide on conditions affecting the lower gastrointestinal tract, such as colitis.

Future Trials

Current federal marijuana regulations make clinical trials using human subjects difficult. Researchers are hoping to partner with the state of Colorado to obtain statistics on the effect of edible marijuana on colitis sufferers. That evidence could support the use of medicinal marijuana to treat severe gastrointestinal disorders.

Future research will focus on finding the specific molecular pathway anandamide uses to send signals between the stomach and the brain. The team is also investigating how anandamide reacts with other receptors, and the functions they serve.

Nandini Acharyaa, Sasi Penukondab, Tatiana Shcheglovaa, Adam T. Hagymasia, Sreyashi Basua,1, and Pramod K. Srivastavaa,1, April 24 issue of the journal Proceedings of the National Academy of Science, Endocannabinoid system acts as a regulator of immune homeostasis in the gut, Nandini Acharya, doi: 10.1073/pnas.1612177114

See more here:
Chili Pepper and Marijuana Soothe Gut Inflammation - Anti Aging News

Japan's radical policy to fight ageing – The Australian Financial Review

Japan, with its rapidly ageing population, has an obvious interest in developing regenerative medicine technology.

Bold, world-leading reform is not something usually associated with Japan or its latest policy push, Abenomics.

But there is one area where the country and its unusually long-serving Prime Minister, Shinzo Abe, can claim global leadership and that is in the field of regenerative medicine.

This relatively new area mostly involves using stem cells and the bodies own healing mechanisms to regrow cartilage or tissue and thereby avoid the need for surgery in difficult to fix areas like shoulders and hips.

Japan, with its rapidly ageing population, has an obvious interest in developing such technologies and has cleared away onerous regulation around clinical trials to kick-start the regenerative medicine industry.

"It was such a radical step," said Paul Anderson, the managing director of the ASX-listed Orthocell.

"And it has totally transformed the industry which has enabled Japan to drawn in capital and technology from around the world."

Buoyed by this success Japan is now looking to convince other countries, including Australia, on the merits its "light touch" regulation, while also looking to commercialise world-leading treatments.

That saw a delegation from the Australian industry accompany Trade Minister Steve Ciobo to Tokyo last week, where they met with Japanese regulators and companies who sold them on the benefits of commercialising their technologies in Japan.

Not that Anderson from Orthocell or John Martin, the chief executive of Regeneus - which is also listed on the ASX - needed much convincing.

"Japan wants to get in early on this revolution," said Martin.

"They are looking to hoover up all the best technologies from around the world and Australia seems to have a lot of them."

This would be a surprise to many given all the teeth gnashing around the lack of innovation in Australia. But contrary to the prevailing narrative it seems Australian companies have once again found a way to get in on the ground floor of a new, fast growing industry as the likes of Cochlear, ResMed and CSL did before them.

The ASX-listed Mesoblast, which was also on the trip to Tokyo, is the world's largest pure play stem cell company, and has had some recent success around treatments for heart failure.

Then come the likes of Orthocell, which recently did a deal with global giant Johnson & Johnson, while in December Regeneus struck a $US16.5 million agreement to license one part of its arthritis technology with Japan's AGC Asahi Glass.

The issue for Australia is that while it has a strong cluster of early stage companies in the space, the local regulatory environment is not as bold or progressive as that in Japan.

"If your regulations are too tough you stifle innovation," said Anderson from Orthocell.

And so the local industry is now pushing for Australia's Therapeutic Goods Administration to adopt the same licensing environment as Japan.

"If you asked me what I really wanted .... it would be that licensed in Japan meant licensed in Australia," said Martin, who was previously a partner at law firm Allens.

This is some way off and would be a big step for the TGA as the radical part of the Japanese approach was how it turned conventional regulatory practice on its head.

Having missed the earlier antibody revolution (mainly around cancer drugs), Japan is betting big that regenerative medicine is the way of the future.

It aims to roughly halve the time it takes to commercials drugs.

This is done by licensing early stage technologies, which are proven safe, then giving them five to seven years to show they can have a meaningful health outcome.

Critics argued this could legalises inefficient treatments, but the Japanese saw the problem through a different lens and decided the cost of delaying true anti-aging therapies was greater than the risk of approving ineffective treatments.

"When Japan first did this it was considered radical and dangerous," said Martin.

"Now there is an emerging view that cell therapies will replace steroids for a wide range of inflammatory conditions."

This push to make Japan a world leader is being led by Abe himself, who has likened Japan's fight against ageing to the battle waged by the US against cholera in the 19th century.

"I will lead the efforts to carve out a new horizon for the latest medical technologies, including regenerative medicine and innovative drug development, through a streamlined system from research to practical application in which the public and private sectors work together," Abe told the Japan National Press club in April 2013, during a speech in which he laid out his vision for the country.

For Abe the push into regenerative medicine is part of the so called "third arrow" of Abenomics, which is aims to boost longer term growth through structural reform the first two arrows were monetary easing and fiscal consolidation.

As promised Abe did change the relevant laws in 2014 and the market has gradually come to see Japan as a world leader in regulating regenerative medicine.

But it lacks the early stage science of Australia, which is why it invited a local delegation to accompany the Trade Minister to Tokyo last week.

Now the question for Australia is whether it will allow its technologies to once again be licensed offshore and for Japan to receive much of the benefit or will take a bold step and follow Abe into the regenerative medicine revolution.

Link:
Japan's radical policy to fight ageing - The Australian Financial Review

UVA Gene Mutation Research Method Speeds Precision Medicine – Health IT Analytics

Source: Thinkstock

April 25, 2017 -A team from the University of Virginia School of Medicine has developed a quicker way to examine the impact of gene mutation on patient health, potentially changing the way cancer labs conduct research into precision medicine and personalized therapies.

The methodology, which uses a virus similar to HIV to replace normal genes with specific mutations, may even be speedier and more cost effective than the CRISPR gene editing technology that currently forms the basis for much of the industrys cutting-edge genomics work.

"Every patient shouldn't receive the same treatment. No way. Not even if they have the same syndrome, the same disease," said UVA researcher J. Julius Zhu, PhD, who led the team that created the new technique. "It's very individual in the patient, and they have to be treated in different ways."

The process of understanding and testing a specific mutations impact on disease development and the usefulness of particular therapies has thus far been slow and painful, said Zhu, who holds positions in UVA's Department of Pharmacology and the UVA Cancer Center.

"You can do one gene and one mutation at a time, he said. Even with the CRISPR [gene editing] technology we have now, it still costs a huge amount of money and time and most labs cannot do it, so we wanted to develop something simple every lab can do. No other approach is so efficient and fast right now.

In addition to ramping up the velocity of studying gene mutations, the new approach may be able to reduce failures in the research process by giving researchers a more sensitive, targeted way to stimulate gene activity.

"The problem in the cancer field is that they have many high-profile papers of clinical trials [that] all failed in some way," Zhu said. "We wondered why in these patients sometimes it doesn't work, that with the same drug some patients are getting better and some are getting worse. The reason is that you don't know which drugs are going to help with their particular mutation. So that would be true precision medicine: You have the same condition, the same syndrome, but a different mutation, so you have to use different drugs."

Zhu has already used the method to analyze approximately 50 mutation of the BRaf gene, which has been tied to tumor development and certain neurodevelopmental disorders. He envisions that the technique will also help unlock the secrets of other diseases, such as Alzheimers, cystic fibrosis, and a variety of cancers all of which are top priorities for precision medicine researchers.

As the marketplace for targeted therapies and associated precision medicine technologies approaches the $100 billion mark, techniques that can help cancer researchers accelerate the development of new treatments will continue to be in high demand.

Drastically reducing the time from hypothesis to bedside will likely produce financial benefits for research labs as well as clinical benefits for patients.

You'd need to spend 10 years to do what we are doing in three months, so it's an entirely different scale, said Zhu. Now, hopefully, we can do 40 or 100 of them simultaneously."

Read more from the original source:
UVA Gene Mutation Research Method Speeds Precision Medicine - Health IT Analytics

Arizona State coach talks team chemistry for regionals – Golf Channel

Arizona State coach talks team chemistry for regionals
Golf Channel
Arizona State coach talks team chemistry for regionals. Arizona State women's golf head coach Missy Farr-Kaye and her team are excited to be the No. 2 seed in the Lubbock Regional for 2017 NCAA Division I Women's Golf Regionals. PlaylistTrending.

and more »

More:
Arizona State coach talks team chemistry for regionals - Golf Channel

Syrian refugee in Romania: ISIS banned chemistry and biology – EURACTIV

In recent years, the Syrian community in Romania grew due to the ongoing civil war. They say they like Romania. They have their school there. But still, the refugees wish to eventually return home, they told EURACTIV.ro.

We met some of them at the Tichrin Arabic School. They came from Syria, some of them years ago, others just recently. They are professors and teach the Arab children English, mathematics, Romanian language, chemistry, physics and other disciplines.

They did not come locked in a truck, they did not cross the sea in an inflatable boat along with dozens of other people. Still, the ones that came, in the recent years, had the same reason for which tens of thousands risk their lives on the road: the conflict in Syria.

They are part of the intellectual class of Syria. At home, they had everything they needed. They had status. Even if they support the Assad regime, the consequences of the conflict are the same for them. ISIS and the absurd rules they had to obey forced them to leave. Romania has become a second home for them.

Some years ago, an ambitious Kurd from a village in northern Syria won a scholarship to study abroad. He ended up in Havana, where he learned Spanish. Elias later returned to Syria, where he became a translator at the state news agency, SANA. EURACTIV Romania reports.

They remember what they went through in Syria, the way they lost their relatives or how they cheated death by choosing to leave. Still, they hope that the conflicts will end and that they will be able to return home. Until then, they have found a purpose in Romania.

Amal, the English teacher

My husband is a dentist. He has studied in Romania 20 years ago. When armed groups occupied the area where we lived, we thought that the best idea would be to come here in Romania. At first, I didnt want to leave and we waited more than we should have. I can still remember how my child used to put his fingers into his ears not to hear the gunshots around. He said I do not want to die! I do not want to die! Why are the armed groups attacking?

I remember something that affected me badly. One day, when I was taking my child to an exam, some masked men came before us. Why are you walking like that? Why are you dressed like that? they asked. Where are you going? Later you will not be able to do what you want anymore. We will be able to do anything. Something like that What is more, explosions were everywhere, all day and all night long. After that, we came here.

We decided we should come to Romania because my husband had been here before, and we could come legally.

I am not sure if there is an intact wall left of our house.

We left everything in Syria. My husband had a factory, a medical cabinet. We believe that if Syria will become peaceful again, we will surely return there. In Syria, in our country, people are peaceful. It is very strange what happened there.

In Romania, I work as an English teacher at Arabic School.

I know nothing of what is happening back home. The whole family left from there.

I just returned from Syria a week ago. There are entire areas destroyed, where the terrorists are located. I lived in Romania. My parents came many years ago. I went to school here, I worked here, but I want to go back to Syria, to do something there too. I mean, I did something here and now I wanted to do something there as well.

I am born in Romania, but I seriously think of doing something in Syria, just like other young people, to implement in Syria everything that we have learned.

Salman Assad, the manager of the Syrian Arabic School

In Damascus, it was totally safe up until problems started to appear. The boutiques and stores were left open when their owners had to leave for somewhere. They used to put a chair in front of the door, and nobody entered. The stores remained open. Who would come to steal? Nobody would.

You stop your car, leave the window open, the car open You have your bag there I am not exaggerating. I am telling the truth, sir. You return to your car 2, 3, 4 hours later. It is perfect, as you left it. To be perfectly fair, something can happen, but it is 1 in 100 cases. That is normal. But in general, that is Syria.

For us, Romania is the second country. I am a Syrian, and now Im also Romanian. I went to school here, and afterwards, I returned to Syria, after my PhD. I came back to serve in the army. I did not run from the army. That is the truth. I came back. I served. I worked. Then, I returned here (to Romania) without planning to live here. I came and after a while, I started to think that I want to help my child to learn. Darin was in the first grade. Her mother was in charge with education and she wanted to teach the children, so she did a class at home a school at home. This is where the idea to create a school was born.

Romania has a long history with Syria. If Romanian considers Syria It is logical We are brothers. Romanians get along very well with Syrians. It is a great thing and thats why I like Romania so much.

If you would say to me Go to Switzerland, the biggest villa, the biggest car, the largest salary. Live there in Geneva or live here in Bucharest. Honestly, I prefer to leave here, pure and simple, without even thinking about it.

The Romanian from Homs

My father is Syrian. I am a Syrian and a Romanian as well. My mother is a Romanian. I was born in Romania. Then, in 1999, we went back to Syria. I stayed there until 2016. We had the possibility to come back to Romania anytime we wanted.

In Homs, the bombings began in 2012. The city was freed from terrorists and placed again under the government rule.

We held together. We fled to Damascus, where we stayed for a year. Afterwards, we returned home, but we did not manage to escape the danger. Our house was destroyed after two explosions and I could not take it anymore. Ive lost my house and two cousins in the explosion. We came back to Romania temporarily. After everything is finished, I will go back to Homs, to the ruins that I left behind and rebuild our home.

I teach chemistry. In Deir ez-Zor, for example, they banned chemistry for heresy. What does that mean, chemistry is heresy? The Islamic State, these terrorists banned chemistry because they said it is from the devil. Biology was banned as well. They say that trying to understand the science of creation meddles with the science of God It should be prohibited. They banned biology and chemistry. They are not normal people. In reality, Islam encourages science, it is not against it, Islam encourages education. The Islamic State is not Islam. We are Muslims and we know that.

View original post here:
Syrian refugee in Romania: ISIS banned chemistry and biology - EURACTIV

Humans alter Earth’s chemistry from beyond grave – Daily Sabah

The focus of man's impact on nature is often based on live interaction, however, our decomposing corpses also alter the delicate chemical balance in the soil after death, scientists warned on Wednesday.

Whether our bodies are buried or cremated, they leach iron, zinc, sulfur, calcium and phosphorus into ground that may later be used in farms, forests or parks.

While essential as general nutrients, human funerary practices mean the elements are being concentrated in cemeteries instead of being dispersed evenly throughout nature, according to new research.

As a result, in some places the nutrients are overly concentrated for optimal absorption by plants and creatures, while deficient in others.

Furthermore, human bodies also contain more sinister elements, such as mercury from dental fillings.

"Chemical traces of decomposed bodies can frequently be very well distinguished in soil," said Ladislav Smejda of the Czech University of Life Sciences in Prague, who took part in the unusual probe.

"These traces persist for a very long time, often for centuries to millennia," explained Smejda.

"The effects will become more pronounced as more and more dead bodies are laid to rest," Smejda said in Vienna, where he unveiled the research at a meeting of the European Geosciences Union.

"What we do today with our dead will affect the environment for a very, very long time," he said.

"Maybe it is not a huge problem in our current perspective, but with an increasing global population, it might become a pressing problem in the future."

Smejda and a team used X-ray fluorescence spectroscopy to analyze soil chemicals in graves and ash "scattering gardens."

Pushing up daisies

Using animal carcasses, they also measured the theoretical impact of an ancient practice called "excarnation," where the dead are left out in the open for nature to take its course.

In all three cases, the ground contained "significantly" higher concentrations of chemicals compared to its surroundings, Smejda said.

If cemeteries did not exist, human remains, like those of animals, would be distributed randomly and the nutrients they release would be reused "again and again, everywhere," the researcher told AFP.

"[But concentrating them in certain places] is something that can be regarded as not natural. It's human impact, and we are changing natural levels," he said.

Now the question is: "Can we come up with a better idea [of] how to distribute these necessary elements across wider landscapes?" Smejda added.

"Certainly it is potentially possible to invent, develop and put into practice ... new methods of human burial or new treatments that could be more environmentally friendly, more ecological," he added.

He conceded this was a "taboo" topic for many with funerary customs deeply rooted in culture and religion.

"It's a very complex matter, and we are only at the beginning of this discussion, I think," he said.

See the original post here:
Humans alter Earth's chemistry from beyond grave - Daily Sabah

3SBio: Is this Chinese Biotechnology Stock a Buy? – Barron’s


Barron's
3SBio: Is this Chinese Biotechnology Stock a Buy?
Barron's
Shenyang-based 3SBio (1530.HK) is a biopharmaceutical pioneer that offers a unique play on China's rising demand for healthcare. The company is best known for its rheumatoid arthritis drug YSP, which accounts for 33% of revenues, and TPIAO, ...

Follow this link:
3SBio: Is this Chinese Biotechnology Stock a Buy? - Barron's

iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc. – The Cerbat Gem

iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc.
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research note issued to investors on Wednesday. They currently have $301.57 price target on ...
iShares NASDAQ Biotechnology Index (IBB) Stake Raised by Mycio Wealth Partners LLCSports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Position Lowered by Bartlett & Co. LLCBBNS
The Crestwood Advisors Group LLC Acquires 5651 Shares of iShares NASDAQ Biotechnology Index (IBB)Petro Global News 24

all 6 news articles »

Follow this link:
iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc. - The Cerbat Gem

Syrris Asia flow chemistry, designed for you – Technology Networks

Flow chemistry presents an opportunity for you to enhance your chemistry. The main advantages compared to traditional batch techniques include increased safety, speed, and selectivity, the ability to discover new chemistry (or access previously restricted chemistry) and offering easy access to scale-up.

Syrris is the longest established provider of laboratory scale flow chemistry systems, Syrris wealth of expertise in research and development has propelled the modular Asia product line to the forefront of the flow chemistry market.

Asia is a revolutionary range of advanced flow chemistry products from Syrris. It has been designed by chemists for chemists to enable the widest variety of chemical reactions and ultimate ease of use.

Asia offers a variety of flow chemistry modules and systems in either entry level or advanced configurations for both beginners with modest budgets and experts who demand the utmost functionality. The unique benefits of flow chemistry make it a suitable tool for a wide range of applications.

Well prove your chemistry can be performed better in flow. Contact our in-house experts today if you have an application in mind and we can advise you on how to enhance your chemistry.

Read the rest here:
Syrris Asia flow chemistry, designed for you - Technology Networks